Selected research
Industry Research
Human Coagulation Factor Ⅷ Industry Research Report 2026
Market perspective
The global Human Coagulation Factor Ⅷ market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Human Coagulation Factor Ⅷ market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Human Coagulation Factor Ⅷ market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Human Coagulation Factor Ⅷ market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Human Coagulation Factor Ⅷ include Taibang Bio, Guangdong Shuanglin, Shanghai Laishi, GreenCross, Pfizer, Pfizer, Hualan Bio, Bayer and Baxter, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Human Coagulation Factor Ⅷ market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Human Coagulation Factor Ⅷ.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Human Coagulation Factor Ⅷ Market by Company
Taibang Bio
Guangdong Shuanglin
Shanghai Laishi
GreenCross
Pfizer
Pfizer
Hualan Bio
Bayer
Baxter
Octapharma
Grifols
CSL Behring
Human Coagulation Factor Ⅷ Segment by Type
Recombinant Factor VIII
Human Factor VIII
Human Coagulation Factor Ⅷ Segment by Application
Relvent Bleeding Diseases
Hemophilia A
Human Coagulation Factor Ⅷ Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Coagulation Factor Ⅷ market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Coagulation Factor Ⅷ and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Coagulation Factor Ⅷ.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Human Coagulation Factor Ⅷ companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Recombinant Factor VIII
- Human Factor VIII
Applications
- Relvent Bleeding Diseases
- Hemophilia A
Companies covered
- Taibang Bio
- Guangdong Shuanglin
- Shanghai Laishi
- GreenCross
- Pfizer
- Pfizer
- Hualan Bio
- Bayer
- Baxter
- Octapharma
- Grifols
- CSL Behring
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Human Coagulation Factor Ⅷ by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Recombinant Factor VIII
- 2.2.3 Human Factor VIII
- 2.3 Human Coagulation Factor Ⅷ by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Relvent Bleeding Diseases
- 2.3.3 Hemophilia A
- 2.4 Assumptions and Limitations
3 Human Coagulation Factor Ⅷ Breakdown Data by Type
- 3.1 Global Human Coagulation Factor Ⅷ Historic Market Size by Type (2021-2026)
- 3.2 Global Human Coagulation Factor Ⅷ Forecasted Market Size by Type (2027-2032)
4 Human Coagulation Factor Ⅷ Breakdown Data by Application
- 4.1 Global Human Coagulation Factor Ⅷ Historic Market Size by Application (2021-2026)
- 4.2 Global Human Coagulation Factor Ⅷ Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Human Coagulation Factor Ⅷ Market Perspective (2021-2032)
- 5.2 Global Human Coagulation Factor Ⅷ Growth Trends by Region
- 5.2.1 Global Human Coagulation Factor Ⅷ Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Human Coagulation Factor Ⅷ Historic Market Size by Region (2021-2026)
- 5.2.3 Human Coagulation Factor Ⅷ Forecasted Market Size by Region (2027-2032)
- 5.3 Human Coagulation Factor Ⅷ Market Dynamics
- 5.3.1 Human Coagulation Factor Ⅷ Industry Trends
- 5.3.2 Human Coagulation Factor Ⅷ Market Drivers
- 5.3.3 Human Coagulation Factor Ⅷ Market Challenges
- 5.3.4 Human Coagulation Factor Ⅷ Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Human Coagulation Factor Ⅷ Players by Revenue
- 6.1.1 Global Top Human Coagulation Factor Ⅷ Players by Revenue (2021-2026)
- 6.1.2 Global Human Coagulation Factor Ⅷ Revenue Market Share by Players (2021-2026)
- 6.2 Global Human Coagulation Factor Ⅷ Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Human Coagulation Factor Ⅷ Head Office and Area Served
- 6.4 Global Human Coagulation Factor Ⅷ Players, Product Type & Application
- 6.5 Global Human Coagulation Factor Ⅷ Manufacturers Established Date
- 6.6 Global Human Coagulation Factor Ⅷ Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Human Coagulation Factor Ⅷ Market Size (2021-2032)
- 7.2 North America Human Coagulation Factor Ⅷ Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Human Coagulation Factor Ⅷ Market Size by Country (2021-2026)
- 7.4 North America Human Coagulation Factor Ⅷ Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Human Coagulation Factor Ⅷ Market Size (2021-2032)
- 8.2 Europe Human Coagulation Factor Ⅷ Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Human Coagulation Factor Ⅷ Market Size by Country (2021-2026)
- 8.4 Europe Human Coagulation Factor Ⅷ Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Human Coagulation Factor Ⅷ Market Size (2021-2032)
- 9.2 Asia-Pacific Human Coagulation Factor Ⅷ Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Human Coagulation Factor Ⅷ Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Human Coagulation Factor Ⅷ Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Human Coagulation Factor Ⅷ Market Size (2021-2032)
- 10.2 South America Human Coagulation Factor Ⅷ Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Human Coagulation Factor Ⅷ Market Size by Country (2021-2026)
- 10.4 South America Human Coagulation Factor Ⅷ Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Human Coagulation Factor Ⅷ Market Size (2021-2032)
- 11.2 Middle East & Africa Human Coagulation Factor Ⅷ Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Human Coagulation Factor Ⅷ Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Human Coagulation Factor Ⅷ Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Taibang Bio
- 12.1.1 Taibang Bio Company Information
- 12.1.2 Taibang Bio Business Overview
- 12.1.3 Taibang Bio Revenue in Human Coagulation Factor Ⅷ Business (2021-2026)
- 12.1.4 Taibang Bio Human Coagulation Factor Ⅷ Product Portfolio
- 12.1.5 Taibang Bio Recent Developments
- 12.2 Guangdong Shuanglin
- 12.2.1 Guangdong Shuanglin Company Information
- 12.2.2 Guangdong Shuanglin Business Overview
- 12.2.3 Guangdong Shuanglin Revenue in Human Coagulation Factor Ⅷ Business (2021-2026)
- 12.2.4 Guangdong Shuanglin Human Coagulation Factor Ⅷ Product Portfolio
- 12.2.5 Guangdong Shuanglin Recent Developments
- 12.3 Shanghai Laishi
- 12.3.1 Shanghai Laishi Company Information
- 12.3.2 Shanghai Laishi Business Overview
- 12.3.3 Shanghai Laishi Revenue in Human Coagulation Factor Ⅷ Business (2021-2026)
- 12.3.4 Shanghai Laishi Human Coagulation Factor Ⅷ Product Portfolio
- 12.3.5 Shanghai Laishi Recent Developments
- 12.4 GreenCross
- 12.4.1 GreenCross Company Information
- 12.4.2 GreenCross Business Overview
- 12.4.3 GreenCross Revenue in Human Coagulation Factor Ⅷ Business (2021-2026)
- 12.4.4 GreenCross Human Coagulation Factor Ⅷ Product Portfolio
- 12.4.5 GreenCross Recent Developments
- 12.5 Pfizer
- 12.5.1 Pfizer Company Information
- 12.5.2 Pfizer Business Overview
- 12.5.3 Pfizer Revenue in Human Coagulation Factor Ⅷ Business (2021-2026)
- 12.5.4 Pfizer Human Coagulation Factor Ⅷ Product Portfolio
- 12.5.5 Pfizer Recent Developments
- 12.6 Pfizer
- 12.6.1 Pfizer Company Information
- 12.6.2 Pfizer Business Overview
- 12.6.3 Pfizer Revenue in Human Coagulation Factor Ⅷ Business (2021-2026)
- 12.6.4 Pfizer Human Coagulation Factor Ⅷ Product Portfolio
- 12.6.5 Pfizer Recent Developments
- 12.7 Hualan Bio
- 12.7.1 Hualan Bio Company Information
- 12.7.2 Hualan Bio Business Overview
- 12.7.3 Hualan Bio Revenue in Human Coagulation Factor Ⅷ Business (2021-2026)
- 12.7.4 Hualan Bio Human Coagulation Factor Ⅷ Product Portfolio
- 12.7.5 Hualan Bio Recent Developments
- 12.8 Bayer
- 12.8.1 Bayer Company Information
- 12.8.2 Bayer Business Overview
- 12.8.3 Bayer Revenue in Human Coagulation Factor Ⅷ Business (2021-2026)
- 12.8.4 Bayer Human Coagulation Factor Ⅷ Product Portfolio
- 12.8.5 Bayer Recent Developments
- 12.9 Baxter
- 12.9.1 Baxter Company Information
- 12.9.2 Baxter Business Overview
- 12.9.3 Baxter Revenue in Human Coagulation Factor Ⅷ Business (2021-2026)
- 12.9.4 Baxter Human Coagulation Factor Ⅷ Product Portfolio
- 12.9.5 Baxter Recent Developments
- 12.10 Octapharma
- 12.10.1 Octapharma Company Information
- 12.10.2 Octapharma Business Overview
- 12.10.3 Octapharma Revenue in Human Coagulation Factor Ⅷ Business (2021-2026)
- 12.10.4 Octapharma Human Coagulation Factor Ⅷ Product Portfolio
- 12.10.5 Octapharma Recent Developments
- 12.11 Grifols
- 12.11.1 Grifols Company Information
- 12.11.2 Grifols Business Overview
- 12.11.3 Grifols Revenue in Human Coagulation Factor Ⅷ Business (2021-2026)
- 12.11.4 Grifols Human Coagulation Factor Ⅷ Product Portfolio
- 12.11.5 Grifols Recent Developments
- 12.12 CSL Behring
- 12.12.1 CSL Behring Company Information
- 12.12.2 CSL Behring Business Overview
- 12.12.3 CSL Behring Revenue in Human Coagulation Factor Ⅷ Business (2021-2026)
- 12.12.4 CSL Behring Human Coagulation Factor Ⅷ Product Portfolio
- 12.12.5 CSL Behring Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst